Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

473 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial.
Hirschfield GM, Arndtz K, Kirkham A, Chen YY, Fox R, Rowe A, Douglas-Pugh J, Thorburn D, Barnes E, Aithal GP, Hull D, Bhandal K, Olsen K, Woodward P, Lax S, Newsome P, Smith DJ, Kallio A, Adams DH, Homer V, Weston CJ. Hirschfield GM, et al. Among authors: thorburn d. Hepatol Commun. 2024 Apr 26;8(5):e0426. doi: 10.1097/HC9.0000000000000426. eCollection 2024 May 1. Hepatol Commun. 2024. PMID: 38668724 Free article. Clinical Trial.
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, Karsdal MA, Jaros MJ, Ling L, Kim KH, Rossi SJ, Somaratne RM, DePaoli AM, Beuers U. Hirschfield GM, et al. Among authors: thorburn d. J Hepatol. 2019 Mar;70(3):483-493. doi: 10.1016/j.jhep.2018.10.035. Epub 2018 Nov 9. J Hepatol. 2019. PMID: 30414864 Free article. Clinical Trial.
Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.
Goode EC, Clark AB, Mells GF, Srivastava B, Spiess K, Gelson WTH, Trivedi PJ, Lynch KD, Castren E, Vesterhus MN, Karlsen TH, Ji SG, Anderson CA, Thorburn D, Hudson M, Heneghan MA, Aldersley MA, Bathgate A, Sandford RN, Alexander GJ, Chapman RW, Walmsley M; UK-PSC Consortium; Hirschfield GM, Rushbrook SM. Goode EC, et al. Among authors: thorburn d. Hepatology. 2019 May;69(5):2120-2135. doi: 10.1002/hep.30479. Epub 2019 Mar 4. Hepatology. 2019. PMID: 30566748 Free PMC article.
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Lammers WJ, Hansen BE, van der Meer AJ. Harms MH, et al. Among authors: thorburn d. J Hepatol. 2019 Aug;71(2):357-365. doi: 10.1016/j.jhep.2019.04.001. Epub 2019 Apr 11. J Hepatol. 2019. PMID: 30980847
Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells.
Mulcahy V, Liaskou E, Martin JE, Kotagiri P, Badrock J, Jones RL, Rushbrook SM, Ryder SD, Thorburn D, Taylor-Robinson SD, Clark G, Cordell HJ, Sandford RN, Jones DE, Hirschfield GM, Mells GF. Mulcahy V, et al. Among authors: thorburn d. Hepatol Commun. 2023 Apr 4;7(4):e0110. doi: 10.1097/HC9.0000000000000110. eCollection 2023 Apr 1. Hepatol Commun. 2023. PMID: 37026715 Free PMC article.
Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.
Bowlus CL, Eksteen B, Cheung AC, Thorburn D, Moylan CA, Pockros PJ, Forman LM, Dorenbaum A, Hirschfield GM, Kennedy C, Jaecklin T, McKibben A, Chien E, Baek M, Vig P, Levy C. Bowlus CL, et al. Among authors: thorburn d. Hepatol Commun. 2023 May 15;7(6):e0153. doi: 10.1097/HC9.0000000000000153. eCollection 2023 Jun 1. Hepatol Commun. 2023. PMID: 37184523 Free PMC article.
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.
Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HLA, Hansen BE; Global PBC Study Group. Cheung AC, et al. Among authors: thorburn d. Clin Gastroenterol Hepatol. 2019 Sep;17(10):2076-2084.e2. doi: 10.1016/j.cgh.2018.12.028. Epub 2019 Jan 4. Clin Gastroenterol Hepatol. 2019. PMID: 30616022 Free article.
UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis.
Abbas N, Culver EL, Thorburn D, Halliday N, Crothers H, Dyson JK, Phaw A, Aspinall R, Khakoo SI, Kallis Y, Smith B, Patanwala I, McCune A, Chimakurthi CR, Hegade V, Orrell M, Jones R, Mells G, Thain C, Thain RM, Jones D, Hirschfield G, Trivedi PJ. Abbas N, et al. Among authors: thorburn d. Clin Gastroenterol Hepatol. 2023 Jun;21(6):1561-1570.e13. doi: 10.1016/j.cgh.2022.07.038. Epub 2022 Aug 9. Clin Gastroenterol Hepatol. 2023. PMID: 35961518 Free article.
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
Corpechot C, Chazouillères O, Belnou P, Montano-Loza AJ, Mason A, Ebadi M, Eurich D, Chopra S, Jacob D, Schramm C, Sterneck M, Bruns T, Reuken P, Rauchfuss F, Roccarina D, Thorburn D, Gerussi A, Trivedi P, Hirschfield G, McDowell P, Nevens F, Boillot O, Bosch A, Giostra E, Conti F, Poupon R, Parés A, Reig A, Donato MF, Malinverno F, Floreani A, Russo FP, Cazzagon N, Verhelst X, Goet J, Harms M, van Buuren H, Hansen B, Carrat F, Dumortier J; Global PBC Study Group. Corpechot C, et al. Among authors: thorburn d. J Hepatol. 2020 Sep;73(3):559-565. doi: 10.1016/j.jhep.2020.03.043. Epub 2020 Apr 7. J Hepatol. 2020. PMID: 32275981
473 results